View ValuationVext Science 향후 성장Future 기준 점검 4/6Vext Science은 연간 수입과 매출이 각각 112.8%와 14.2% 증가할 것으로 예상되고 EPS는 연간 103.3%만큼 증가할 것으로 예상됩니다.핵심 정보112.8%이익 성장률103.25%EPS 성장률Pharmaceuticals 이익 성장23.7%매출 성장률14.2%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트22 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026공시 • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026공시 • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025공시 • Oct 13Vext Science, Inc., Annual General Meeting, Dec 11, 2025Vext Science, Inc., Annual General Meeting, Dec 11, 2025.공시 • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025공시 • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025공시 • Apr 01Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC.Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025. Vext Science utilize a non-cash consideration in the transaction. For the period end date December 31, 2024, Vapen Kentucky, LLC reported $46.3 million revenue and $3.3 million net assets based on the equity accounted investment of Vext Science. Vext Science, Inc. (CNSX:VEXT) completed the acquisition of the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025.공시 • Mar 20Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025공시 • Nov 07Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024Vext Science, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 21, 2024공시 • Oct 15Vext Science, Inc., Annual General Meeting, Dec 13, 2024Vext Science, Inc., Annual General Meeting, Dec 13, 2024.Reported Earnings • Aug 21Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.004 profit in 2Q 2023)Second quarter 2024 results: US$0.018 loss per share (down from US$0.004 profit in 2Q 2023). Revenue: US$8.43m (down 8.3% from 2Q 2023). Net loss: US$4.39m (down US$4.93m from profit in 2Q 2023). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.공시 • Aug 09Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024Vext Science, Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 20, 2024공시 • May 26Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024Vext Science, Inc. announced that they will report Q1, 2024 results Pre-Market on May 29, 2024Reported Earnings • May 13Full year 2023 earnings released: EPS: US$0.027 (vs US$0.079 in FY 2022)Full year 2023 results: EPS: US$0.027 (down from US$0.079 in FY 2022). Revenue: US$34.8m (down 1.7% from FY 2022). Net income: US$4.40m (down 60% from FY 2022). Profit margin: 13% (down from 31% in FY 2022). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.공시 • Apr 16Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024Vext Science, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024New Risk • Mar 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€46.5m market cap, or US$50.7m).New Risk • Feb 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (46% increase in shares outstanding). Market cap is less than US$100m (€53.3m market cap, or US$57.4m).공시 • Jan 17Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive RoleVext Science, Inc. announced that Jason Thai Nguyen has transitioned out of his executive positions with the Company, including resigning from all positions with the Company's subsidiaries and affiliates. Mr. Nguyen will continue to serve the Company through his position as a director of the Company and Chairman of the board of directors.Reported Earnings • Nov 29Third quarter 2023 earnings released: US$0.012 loss per share (vs US$0.003 profit in 3Q 2022)Third quarter 2023 results: US$0.012 loss per share (down from US$0.003 profit in 3Q 2022). Revenue: US$8.10m (up 5.6% from 3Q 2022). Net loss: US$1.84m (down US$2.26m from profit in 3Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.공시 • Nov 22Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023Vext Science, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 28, 2023공시 • Oct 14Vext Science, Inc., Annual General Meeting, Dec 15, 2023Vext Science, Inc., Annual General Meeting, Dec 15, 2023.New Risk • Oct 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€39.4m market cap, or US$41.4m).공시 • Oct 13Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.On October 12, 2023, Vext Science, Inc. closed the transaction. The company has now issued 67,647,058 common shares at a price of $0.17 per share for the gross proceeds of $11,500,000. In connection with the offering, the company has paid a cash finder's fee to certain registered dealers consisting of approximately $3,285. The transaction included participation from Mark Opzoomer, Trevor Smith and Sopica Special Opportunities Fund Limited managed by LLF Financial S.A. for 42,798,529 shares. Sopica Special Opportunities Fund Limited purchased 41,176,470 subordinate voting shares for $7,000,000 and its stake is increased by 21.56% (from 13.00% to 34.56%) on a non-diluted basis. Immediately prior to the Private Placement, the Acquirors beneficially owned or otherwise exercised control or direction over 10,726,849 Subordinate Voting Shares, 4,303,182 warrants to purchase Subordinate Voting Shares and 112,486 Class A common shares, representing approximately 26.79% of the issued and outstanding Subordinate Voting Shares. As a result of the Private Placement, the Acquirors beneficially own or otherwise exercise control or direction over 51,903,319 Subordinate Voting Shares, 4,303,182 Warrants and 112,486 Multiple Voting Shares, representing approximately 40.70% of the issued and outstanding Subordinate Voting Shares as at October 12, 2023.Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: US$0.004 (vs US$0.014 in 2Q 2022)Second quarter 2023 results: EPS: US$0.004 (down from US$0.014 in 2Q 2022). Revenue: US$9.19m (up 4.8% from 2Q 2022). Net income: US$535.5k (down 73% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.공시 • Aug 18Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023Vext Science, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 23, 2023공시 • Aug 11+ 1 more updateVext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023Vext Science, Inc. reported that Stephan Bankosz has resigned as CFO and Corporate Secretary of the Company effective August 25, 2023 to pursue other opportunities. Vext will appoint experienced financial executive and operator Trevor Smith as CFO. In the coming weeks Mr. Bankosz will assist with the transition of duties to Mr. Smith, which is expected to be completed after Vext has reported its second quarter 2023 earnings. Nalee Pham, the Company's Chief of Staff and a director of the Company's wholly-owned operating subsidiary Herbal Wellness Center, LLC has been appointed Corporate Secretary.Reported Earnings • May 26First quarter 2023 earnings released: EPS: US$0 (vs US$0.016 in 1Q 2022)First quarter 2023 results: EPS: US$0 (down from US$0.016 in 1Q 2022). Revenue: US$9.11m (down 16% from 1Q 2022). Net income: US$73.1k (down 97% from 1Q 2022). Profit margin: 0.8% (down from 21% in 1Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공시 • May 16Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023Vext Science, Inc. announced that they will report Q1, 2023 results Pre-Market on May 25, 2023Reported Earnings • Mar 23Full year 2022 earnings released: EPS: US$0.079 (vs US$0.036 in FY 2021)Full year 2022 results: EPS: US$0.079 (up from US$0.036 in FY 2021). Revenue: US$35.4m (down 4.9% from FY 2021). Net income: US$10.9m (up 119% from FY 2021). Profit margin: 31% (up from 13% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Board Change • Dec 22Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mark Opzoomer was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.007 in 3Q 2021)Third quarter 2022 results: EPS: US$0.003 (down from US$0.007 in 3Q 2021). Revenue: US$7.67m (down 18% from 3Q 2021). Net income: US$423.5k (down 56% from 3Q 2021). Profit margin: 5.5% (down from 10% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.013 in 2Q 2021)Second quarter 2022 results: EPS: US$0.014 (up from US$0.013 in 2Q 2021). Revenue: US$8.77m (down 6.5% from 2Q 2021). Net income: US$1.95m (up 8.9% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 19%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: US$10.8m (up 18% from 1Q 2021). Net income: US$3.46m (up 204% from 1Q 2021). Profit margin: 32% (up from 12% in 1Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 6.9% growth forecast for the industry in Germany.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Apr 22Full year 2021 earnings released: EPS: US$0.036 (vs US$0.023 in FY 2020)Full year 2021 results: EPS: US$0.036 (up from US$0.023 in FY 2020). Revenue: US$37.2m (up 48% from FY 2020). Net income: US$4.99m (up 135% from FY 2020). Profit margin: 13% (up from 8.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 7.7% growth forecast for the pharmaceuticals industry in Germany.Board Change • Feb 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 19Third quarter 2021 earnings releasedThe company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$9.40m (up 18% from 3Q 2020). Net income: US$970.1k (down 31% from 3Q 2020). Profit margin: 10% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.Reported Earnings • Aug 25Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$9.38m (up 39% from 2Q 2020). Net income: US$1.79m (up 222% from 2Q 2020). Profit margin: 19% (up from 8.3% in 2Q 2020). The increase in margin was driven by higher revenue.Reported Earnings • May 29First quarter 2021 earnings released: EPS US$0.011 (vs US$0.012 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$9.16m (up 124% from 1Q 2020). Net income: US$1.14m (up US$2.11m from 1Q 2020). Profit margin: 12% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue.Reported Earnings • Apr 17Full year 2020 earnings releasedThe company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: US$25.2m (up 13% from FY 2019). Net income: US$2.13m (down 24% from FY 2019). Profit margin: 8.4% (down from 13% in FY 2019). The decrease in margin was driven by higher expenses.Is New 90 Day High Low • Dec 30New 90-day high: €0.66The company is up 141% from its price of €0.27 on 01 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.Reported Earnings • Nov 29Third quarter 2020 earnings released: EPS US$0.017The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$7.95m (up 43% from 3Q 2019). Net income: US$1.41m (up 80% from 3Q 2019). Profit margin: 18% (up from 14% in 3Q 2019). The increase in margin was driven by higher revenue.Is New 90 Day High Low • Nov 29New 90-day high: €0.36The company is up 22% from its price of €0.30 on 31 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Is New 90 Day High Low • Oct 10New 90-day low: €0.24The company is down 21% from its price of €0.30 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period.Is New 90 Day High Low • Sep 23New 90-day low: €0.26The company is down 18% from its price of €0.32 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period.이익 및 매출 성장 예측DB:VV5 - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202874-22014112/31/20276921815212/31/202654-291113/31/202652-16710N/A12/31/202551-18812N/A9/30/202548-17913N/A6/30/202544-17911N/A3/31/202539-1946N/A12/31/202436-2223N/A9/30/202434-8-20N/A6/30/202433-7-10N/A3/31/202434-224N/A12/31/202335424N/A9/30/202335546N/A6/30/202334705N/A3/31/2023349-23N/A12/31/20223511-36N/A9/30/2022376-38N/A6/30/2022386011N/A3/31/2022396-1012N/A12/31/2021375-811N/A9/30/2021345-98N/A6/30/2021335-88N/A3/31/202130426N/A12/31/2020252-13N/A9/30/2020220-22N/A6/30/2020200-61N/A3/31/2020200-60N/A12/31/2019223N/A0N/A9/30/2019234N/A-1N/A6/30/2019235N/A-1N/A3/31/2019214N/A0N/A12/31/2018184N/A2N/A12/31/2017154N/A2N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: VV5 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률(1.9%)보다 빠른 성장으로 간주됩니다.수익 vs 시장: VV5 (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.고성장 수익: VV5 향후 3년 내에 수익을 낼 것으로 예상됩니다.수익 대 시장: VV5 의 수익(연간 14.2%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: VV5 의 수익(연간 14.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: VV5의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/24 18:14종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Vext Science, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Matt BottomleyCanaccord GenuityShaan MirCanaccord GenuityNeal GilmerHaywood Securities Inc.4명의 분석가 더 보기
공시 • May 15Vext Science, Inc. to Report Q1, 2026 Results on May 21, 2026Vext Science, Inc. announced that they will report Q1, 2026 results Pre-Market on May 21, 2026
공시 • Mar 31Vext Science, Inc. to Report Q4, 2025 Results on Apr 23, 2026Vext Science, Inc. announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Apr 23, 2026
공시 • Nov 11Vext Science, Inc. to Report Q3, 2025 Results on Nov 20, 2025Vext Science, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 20, 2025
공시 • Oct 13Vext Science, Inc., Annual General Meeting, Dec 11, 2025Vext Science, Inc., Annual General Meeting, Dec 11, 2025.
공시 • Aug 11Vext Science, Inc. to Report Q2, 2025 Results on Aug 20, 2025Vext Science, Inc. announced that they will report Q2, 2025 results Pre-Market on Aug 20, 2025
공시 • May 13Vext Science, Inc. to Report Q1, 2025 Results on May 21, 2025Vext Science, Inc. announced that they will report Q1, 2025 results Pre-Market on May 21, 2025
공시 • Apr 01Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC.Vext Science, Inc. (CNSX:VEXT) acquired the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025. Vext Science utilize a non-cash consideration in the transaction. For the period end date December 31, 2024, Vapen Kentucky, LLC reported $46.3 million revenue and $3.3 million net assets based on the equity accounted investment of Vext Science. Vext Science, Inc. (CNSX:VEXT) completed the acquisition of the remaining 50% stake in Vapen Kentucky, LLC from Emerald Point Hemp, LLC on March 26, 2025.
공시 • Mar 20Vext Science, Inc. to Report Q4, 2024 Results on Mar 31, 2025Vext Science, Inc. announced that they will report Q4, 2024 results at 9:30 AM, US Eastern Standard Time on Mar 31, 2025
공시 • Nov 07Vext Science, Inc. to Report Q3, 2024 Results on Nov 21, 2024Vext Science, Inc. announced that they will report Q3, 2024 results Pre-Market on Nov 21, 2024
공시 • Oct 15Vext Science, Inc., Annual General Meeting, Dec 13, 2024Vext Science, Inc., Annual General Meeting, Dec 13, 2024.
Reported Earnings • Aug 21Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.004 profit in 2Q 2023)Second quarter 2024 results: US$0.018 loss per share (down from US$0.004 profit in 2Q 2023). Revenue: US$8.43m (down 8.3% from 2Q 2023). Net loss: US$4.39m (down US$4.93m from profit in 2Q 2023). Revenue is forecast to grow 44% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings.
공시 • Aug 09Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024Vext Science, Inc. announced that they will report Q2, 2024 results at 9:30 AM, US Eastern Standard Time on Aug 20, 2024
공시 • May 26Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024Vext Science, Inc. announced that they will report Q1, 2024 results Pre-Market on May 29, 2024
Reported Earnings • May 13Full year 2023 earnings released: EPS: US$0.027 (vs US$0.079 in FY 2022)Full year 2023 results: EPS: US$0.027 (down from US$0.079 in FY 2022). Revenue: US$34.8m (down 1.7% from FY 2022). Net income: US$4.40m (down 60% from FY 2022). Profit margin: 13% (down from 31% in FY 2022). Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings.
공시 • Apr 16Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024Vext Science, Inc. announced that they will report Q4, 2023 results at 9:30 AM, US Eastern Standard Time on Apr 25, 2024
New Risk • Mar 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 64% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (64% increase in shares outstanding). Minor Risk Market cap is less than US$100m (€46.5m market cap, or US$50.7m).
New Risk • Feb 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (46% increase in shares outstanding). Market cap is less than US$100m (€53.3m market cap, or US$57.4m).
공시 • Jan 17Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive RoleVext Science, Inc. announced that Jason Thai Nguyen has transitioned out of his executive positions with the Company, including resigning from all positions with the Company's subsidiaries and affiliates. Mr. Nguyen will continue to serve the Company through his position as a director of the Company and Chairman of the board of directors.
Reported Earnings • Nov 29Third quarter 2023 earnings released: US$0.012 loss per share (vs US$0.003 profit in 3Q 2022)Third quarter 2023 results: US$0.012 loss per share (down from US$0.003 profit in 3Q 2022). Revenue: US$8.10m (up 5.6% from 3Q 2022). Net loss: US$1.84m (down US$2.26m from profit in 3Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
공시 • Nov 22Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023Vext Science, Inc. announced that they will report Q3, 2023 results Pre-Market on Nov 28, 2023
공시 • Oct 14Vext Science, Inc., Annual General Meeting, Dec 15, 2023Vext Science, Inc., Annual General Meeting, Dec 15, 2023.
New Risk • Oct 13New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 57% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (57% increase in shares outstanding). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (€39.4m market cap, or US$41.4m).
공시 • Oct 13Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.On October 12, 2023, Vext Science, Inc. closed the transaction. The company has now issued 67,647,058 common shares at a price of $0.17 per share for the gross proceeds of $11,500,000. In connection with the offering, the company has paid a cash finder's fee to certain registered dealers consisting of approximately $3,285. The transaction included participation from Mark Opzoomer, Trevor Smith and Sopica Special Opportunities Fund Limited managed by LLF Financial S.A. for 42,798,529 shares. Sopica Special Opportunities Fund Limited purchased 41,176,470 subordinate voting shares for $7,000,000 and its stake is increased by 21.56% (from 13.00% to 34.56%) on a non-diluted basis. Immediately prior to the Private Placement, the Acquirors beneficially owned or otherwise exercised control or direction over 10,726,849 Subordinate Voting Shares, 4,303,182 warrants to purchase Subordinate Voting Shares and 112,486 Class A common shares, representing approximately 26.79% of the issued and outstanding Subordinate Voting Shares. As a result of the Private Placement, the Acquirors beneficially own or otherwise exercise control or direction over 51,903,319 Subordinate Voting Shares, 4,303,182 Warrants and 112,486 Multiple Voting Shares, representing approximately 40.70% of the issued and outstanding Subordinate Voting Shares as at October 12, 2023.
Reported Earnings • Aug 23Second quarter 2023 earnings released: EPS: US$0.004 (vs US$0.014 in 2Q 2022)Second quarter 2023 results: EPS: US$0.004 (down from US$0.014 in 2Q 2022). Revenue: US$9.19m (up 4.8% from 2Q 2022). Net income: US$535.5k (down 73% from 2Q 2022). Profit margin: 5.8% (down from 22% in 2Q 2022). Revenue is forecast to grow 42% p.a. on average during the next 2 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
공시 • Aug 18Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023Vext Science, Inc. announced that they will report Q2, 2023 results Pre-Market on Aug 23, 2023
공시 • Aug 11+ 1 more updateVext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023Vext Science, Inc. reported that Stephan Bankosz has resigned as CFO and Corporate Secretary of the Company effective August 25, 2023 to pursue other opportunities. Vext will appoint experienced financial executive and operator Trevor Smith as CFO. In the coming weeks Mr. Bankosz will assist with the transition of duties to Mr. Smith, which is expected to be completed after Vext has reported its second quarter 2023 earnings. Nalee Pham, the Company's Chief of Staff and a director of the Company's wholly-owned operating subsidiary Herbal Wellness Center, LLC has been appointed Corporate Secretary.
Reported Earnings • May 26First quarter 2023 earnings released: EPS: US$0 (vs US$0.016 in 1Q 2022)First quarter 2023 results: EPS: US$0 (down from US$0.016 in 1Q 2022). Revenue: US$9.11m (down 16% from 1Q 2022). Net income: US$73.1k (down 97% from 1Q 2022). Profit margin: 0.8% (down from 21% in 1Q 2022). Revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 3.7% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공시 • May 16Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023Vext Science, Inc. announced that they will report Q1, 2023 results Pre-Market on May 25, 2023
Reported Earnings • Mar 23Full year 2022 earnings released: EPS: US$0.079 (vs US$0.036 in FY 2021)Full year 2022 results: EPS: US$0.079 (up from US$0.036 in FY 2021). Revenue: US$35.4m (down 4.9% from FY 2021). Net income: US$10.9m (up 119% from FY 2021). Profit margin: 31% (up from 13% in FY 2021). The increase in margin was driven by lower expenses. Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Board Change • Dec 22Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Mark Opzoomer was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 18Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.007 in 3Q 2021)Third quarter 2022 results: EPS: US$0.003 (down from US$0.007 in 3Q 2021). Revenue: US$7.67m (down 18% from 3Q 2021). Net income: US$423.5k (down 56% from 3Q 2021). Profit margin: 5.5% (down from 10% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 26Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.013 in 2Q 2021)Second quarter 2022 results: EPS: US$0.014 (up from US$0.013 in 2Q 2021). Revenue: US$8.77m (down 6.5% from 2Q 2021). Net income: US$1.95m (up 8.9% from 2Q 2021). Profit margin: 22% (up from 19% in 2Q 2021). The increase in margin was driven by lower expenses. Over the next year, revenue is forecast to grow 19%, compared to a 6.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Jun 02First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: US$10.8m (up 18% from 1Q 2021). Net income: US$3.46m (up 204% from 1Q 2021). Profit margin: 32% (up from 12% in 1Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 21%, compared to a 6.9% growth forecast for the industry in Germany.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Apr 22Full year 2021 earnings released: EPS: US$0.036 (vs US$0.023 in FY 2020)Full year 2021 results: EPS: US$0.036 (up from US$0.023 in FY 2020). Revenue: US$37.2m (up 48% from FY 2020). Net income: US$4.99m (up 135% from FY 2020). Profit margin: 13% (up from 8.4% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 7.7% growth forecast for the pharmaceuticals industry in Germany.
Board Change • Feb 12Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 3 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director David Eaton is the most experienced director on the board, commencing their role in 2015. Independent Director Jonathan Shelton was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 19Third quarter 2021 earnings releasedThe company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: US$9.40m (up 18% from 3Q 2020). Net income: US$970.1k (down 31% from 3Q 2020). Profit margin: 10% (down from 18% in 3Q 2020). The decrease in margin was driven by higher expenses.
Reported Earnings • Aug 25Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$9.38m (up 39% from 2Q 2020). Net income: US$1.79m (up 222% from 2Q 2020). Profit margin: 19% (up from 8.3% in 2Q 2020). The increase in margin was driven by higher revenue.
Reported Earnings • May 29First quarter 2021 earnings released: EPS US$0.011 (vs US$0.012 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$9.16m (up 124% from 1Q 2020). Net income: US$1.14m (up US$2.11m from 1Q 2020). Profit margin: 12% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue.
Reported Earnings • Apr 17Full year 2020 earnings releasedThe company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: US$25.2m (up 13% from FY 2019). Net income: US$2.13m (down 24% from FY 2019). Profit margin: 8.4% (down from 13% in FY 2019). The decrease in margin was driven by higher expenses.
Is New 90 Day High Low • Dec 30New 90-day high: €0.66The company is up 141% from its price of €0.27 on 01 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 1.0% over the same period.
Reported Earnings • Nov 29Third quarter 2020 earnings released: EPS US$0.017The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$7.95m (up 43% from 3Q 2019). Net income: US$1.41m (up 80% from 3Q 2019). Profit margin: 18% (up from 14% in 3Q 2019). The increase in margin was driven by higher revenue.
Is New 90 Day High Low • Nov 29New 90-day high: €0.36The company is up 22% from its price of €0.30 on 31 August 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Oct 10New 90-day low: €0.24The company is down 21% from its price of €0.30 on 10 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period.
Is New 90 Day High Low • Sep 23New 90-day low: €0.26The company is down 18% from its price of €0.32 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period.